Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Apr;43(4):878-887.
doi: 10.1111/liv.15544. Epub 2023 Feb 28.

Increase of liver stiffness and altered bile acid metabolism after triple CFTR modulator initiation in children and young adults with cystic fibrosis

Alexander Schnell  1 , Jörg Jüngert  1 , Daniel Klett  2 , Hannah Hober  1 , Natalie Kaiser  1 , Renate Ruppel  1 , Annika Geppert  2 , Christina Tremel  1 , Julia Sobel  1 , Erika Plattner  1 , Sabina Schmitt-Grohé  1 , Sabine Zirlik  2 , Deike Strobel  2 , Markus F Neurath  2 , Ferdinand Knieling  1   3 , Manfred Rauh  1 , Joachim Woelfle  1 , André Hoerning  1 , Adrian P Regensburger  1   3
Affiliations
Observational Study

Increase of liver stiffness and altered bile acid metabolism after triple CFTR modulator initiation in children and young adults with cystic fibrosis

Alexander Schnell et al. Liver Int. 2023 Apr.

Abstract

Background: Novel cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies (elexacaftor/tezacaftor/ivacaftor-ETI) promise clinically significant and sustained improvements for patients with cystic fibrosis (CF). In this study, we investigated the impact of ETI therapy on liver stiffness and bile acid metabolism in a cohort of children and young adults with CF.

Methods: A prospective observational study (NCT05576324) was conducted from September 2020 to November 2021 enrolling CF patients naive to ETI. Standard laboratory chemistry, sweat test, lung function, share wave velocity (SWV) derived by acoustic radiation force impulse imaging (ARFI) and serum bile acid profiles were assessed before and 6 months after induction of ETI therapy.

Results: A total of 20 patients (10 aged <20 years) completed the study. While lung function and BMI improved after ETI therapy, ARFI SWV increased in CF patients <20 years of age (from 1.27 to 1.43 m/s, p = 0.023). Bile acid (BA) profiles revealed a decrease in unconjugated (5.75 vs 1.46, p = 0.007) and increase in glycine-conjugated derivatives (GCDCA) (4.79 vs 6.64 p = 0.016). There was a positive correlation between ARFI SWV values and GCDCA (r = 0.80, p < 0.0001). Glycine-conjugated BA provided high diagnostic accuracy to predict increased ARFI measurements (AUC 0.90) and clinical (Colombo) CFLD grading (AUC 0.97).

Conclusions: ARFI SWV and bile acid profiles provide evidence for early increase in liver stiffness and altered bile acid metabolism in young CF patients after initiation of ETI and may serve as synergistic measures for detection of hepatic complications during ETI therapy.

Keywords: ARFI; CFLD; bile acids; cystic fibrosis.

PubMed Disclaimer

References

REFERENCES

    1. Toledano MB, Mukherjee SK, Howell J, et al. The emerging burden of liver disease in cystic fibrosis patients: a UK nationwide study. PLOS One. 2019;14(4):e0212779.
    1. Colombo C, Battezzati PM, Crosignani A, et al. Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology. 2002;36(6):1374-1382.
    1. Boëlle PY, Debray D, Guillot L, Clement A, Corvol H, on behalf of the French CF Modifier Gene Study Investigators. Cystic fibrosis liver disease: outcomes and risk factors in a large cohort of French patients. Hepatology. 2019;69(4):1648-1656.
    1. Zolin A, Bossi A, Cirilli N, Kashirskaya N, Padoan R. Cystic fibrosis mortality in childhood. Data from European cystic fibrosis society patient registry. Int J Environ Res Public Health. 2018;15(9):2020.
    1. Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809-1819.

Publication types

Substances

Associated data